Lenalidomide (Revlimid) for relapsed and/or refractory multiple myeloma - horizon scanning review
NHSC
Record ID 32005001220
English
Authors' objectives:
This study aims to assess the effectiveness of Lenalidomide (Revlimid) for relapsed and/or refractory multiple myeloma.
Authors' recommendations:
Lenalidomide (Revlimid, CC-5013), an oral immunomodulatory thalidomide analogue, is in development for relapsed and/or refractory multiple myeloma (MM). Lenalidomide does not have the teratogenic effects of thalidomide. Two large phase III trials in relapsed and/or refractory MM were unblinded early with significantly greater response rates, and times to progression.
Authors' methods:
Overview
Details
Project Status:
Completed
Year Published:
2005
URL for published report:
http://www.hsric.nihr.ac.uk/search
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Angiogenesis Inhibitors
- Thalidomide
- Multiple Myeloma
- Lenalidomide
- Immunologic Factors
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
NIHR Horizon Scanning Centre (NIHR HSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.